104 related articles for article (PubMed ID: 25941580)
1. Overcoming immunosuppression to enhance a p53MVA vaccine.
Hardwick N; Chung V; Cristea M; Ellenhorn JD; Diamond DJ
Oncoimmunology; 2014 Nov; 3(10):e958949. PubMed ID: 25941580
[TBL] [Abstract][Full Text] [Related]
2. p53-Reactive T Cells Are Associated with Clinical Benefit in Patients with Platinum-Resistant Epithelial Ovarian Cancer After Treatment with a p53 Vaccine and Gemcitabine Chemotherapy.
Hardwick NR; Frankel P; Ruel C; Kilpatrick J; Tsai W; Kos F; Kaltcheva T; Leong L; Morgan R; Chung V; Tinsley R; Eng M; Wilczynski S; Ellenhorn JDI; Diamond DJ; Cristea M
Clin Cancer Res; 2018 Mar; 24(6):1315-1325. PubMed ID: 29301826
[TBL] [Abstract][Full Text] [Related]
3. Immunologic Signatures of Peripheral Blood T Cells Reveal the Outcome of p53MVA Vaccine and Pembrolizumab Treatment in Patients with Advanced Ovarian Cancer.
Kos FJ; Frankel P; Cristea M; Eng M; Tinsley R; Dempsey S; Ruel N; Stewart D; Dellinger TH; Diamond DJ
Cancer Res Commun; 2023 Dec; 3(12):2585-2595. PubMed ID: 38032111
[TBL] [Abstract][Full Text] [Related]
4. p53MVA therapy in patients with refractory gastrointestinal malignancies elevates p53-specific CD8+ T-cell responses.
Hardwick NR; Carroll M; Kaltcheva T; Qian D; Lim D; Leong L; Chu P; Kim J; Chao J; Fakih M; Yen Y; Espenschied J; Ellenhorn JD; Diamond DJ; Chung V
Clin Cancer Res; 2014 Sep; 20(17):4459-70. PubMed ID: 24987057
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of safety and efficacy of p53MVA vaccine combined with pembrolizumab in patients with advanced solid cancers.
Chung V; Kos FJ; Hardwick N; Yuan Y; Chao J; Li D; Waisman J; Li M; Zurcher K; Frankel P; Diamond DJ
Clin Transl Oncol; 2019 Mar; 21(3):363-372. PubMed ID: 30094792
[TBL] [Abstract][Full Text] [Related]
6. Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: Preclinical studies with MVA-βGal and MVA-MUC1 (TG4010) in a murine tumor model.
Remy-Ziller C; Thioudellet C; Hortelano J; Gantzer M; Nourtier V; Claudepierre MC; Sansas B; Préville X; Bendjama K; Quemeneur E; Rittner K
Hum Vaccin Immunother; 2018 Jan; 14(1):140-145. PubMed ID: 28925793
[TBL] [Abstract][Full Text] [Related]
7. Characterization of the
Chevolet I; Speeckaert R; Schreuer M; Neyns B; Krysko O; Bachert C; Hennart B; Allorge D; van Geel N; Van Gele M; Brochez L
Oncoimmunology; 2015 Mar; 4(3):e982382. PubMed ID: 25949897
[TBL] [Abstract][Full Text] [Related]
8. Complete regression of cutaneous metastases with systemic immune response in a patient with triple negative breast cancer receiving p53MVA vaccine with pembrolizumab.
Yuan Y; Kos FJ; He TF; Yin HH; Li M; Hardwick N; Zurcher K; Schmolze D; Lee P; Pillai RK; Chung V; Diamond DJ
Oncoimmunology; 2017; 6(12):e1363138. PubMed ID: 29209571
[TBL] [Abstract][Full Text] [Related]
9. Uptake of antigens from modified vaccinia Ankara virus-infected leukocytes enhances the immunostimulatory capacity of dendritic cells.
Flechsig C; Suezer Y; Kapp M; Tan SM; Löffler J; Sutter G; Einsele H; Grigoleit GU
Cytotherapy; 2011 Jul; 13(6):739-52. PubMed ID: 21250864
[TBL] [Abstract][Full Text] [Related]
10. Vaccination with recombinant modified vaccinia virus Ankara prevents the onset of intestinal allergy in mice.
Bohnen C; Wangorsch A; Schülke S; Nakajima-Adachi H; Hachimura S; Burggraf M; Süzer Y; Schwantes A; Sutter G; Waibler Z; Reese G; Toda M; Scheurer S; Vieths S
Allergy; 2013 Aug; 68(8):1021-8. PubMed ID: 23909913
[TBL] [Abstract][Full Text] [Related]
11. The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer.
Lee JW; Zhang Y; Eoh KJ; Sharma R; Sanmamed MF; Wu J; Choi J; Park HS; Iwasaki A; Kaftan E; Chen L; Papadimitrakopoulou V; Herbst RS; Koo JS
J Thorac Oncol; 2019 Jun; 14(6):1046-1060. PubMed ID: 30771521
[TBL] [Abstract][Full Text] [Related]
12. Improvement of anti-tumor immunity of fibroblast activation protein α based vaccines by combination with cyclophosphamide in a murine model of breast cancer.
Xia Q; Zhang FF; Geng F; Liu CL; Wang YQ; Xu P; Lu ZZ; Xie Y; Wu H; Chen Y; Zhang Y; Kong W; Yu XH; Zhang HH
Cell Immunol; 2016 Dec; 310():89-98. PubMed ID: 27545090
[TBL] [Abstract][Full Text] [Related]
13. Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced, CD34(+)-derived dendritic cell vaccination: a phase I trial in metastatic melanoma.
Di Nicola M; Carlo-Stella C; Mortarini R; Baldassari P; Guidetti A; Gallino GF; Del Vecchio M; Ravagnani F; Magni M; Chaplin P; Cascinelli N; Parmiani G; Gianni AM; Anichini A
Clin Cancer Res; 2004 Aug; 10(16):5381-90. PubMed ID: 15328176
[TBL] [Abstract][Full Text] [Related]
14. TroVax in colorectal cancer.
Rowe J; Cen P
Hum Vaccin Immunother; 2014; 10(11):3196-200. PubMed ID: 25483641
[TBL] [Abstract][Full Text] [Related]
15. 5T4-modified vaccinia Ankara: progress in tumor-associated antigen-based immunotherapy.
Amato RJ
Expert Opin Biol Ther; 2010 Feb; 10(2):281-7. PubMed ID: 20088718
[TBL] [Abstract][Full Text] [Related]
16. Human Immunodeficiency Virus C.1086 Envelope gp140 Protein Boosts following DNA/Modified Vaccinia Virus Ankara Vaccination Fail To Enhance Heterologous Anti-V1V2 Antibody Response and Protection against Clade C Simian-Human Immunodeficiency Virus Challenge.
Styles TM; Gangadhara S; Reddy PBJ; Hicks S; LaBranche CC; Montefiori DC; Derdeyn CA; Kozlowski PA; Velu V; Amara RR
J Virol; 2019 Oct; 93(20):. PubMed ID: 31341049
[TBL] [Abstract][Full Text] [Related]
17. Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model.
Meseda CA; Garcia AD; Kumar A; Mayer AE; Manischewitz J; King LR; Golding H; Merchlinsky M; Weir JP
Virology; 2005 Sep; 339(2):164-75. PubMed ID: 15993917
[TBL] [Abstract][Full Text] [Related]
18. Preferential Targeting of Conserved Gag Regions after Vaccination with a Heterologous DNA Prime-Modified Vaccinia Virus Ankara Boost HIV-1 Vaccine Regimen.
Bauer A; Podola L; Mann P; Missanga M; Haule A; Sudi L; Nilsson C; Kaluwa B; Lueer C; Mwakatima M; Munseri PJ; Maboko L; Robb ML; Tovanabutra S; Kijak G; Marovich M; McCormack S; Joseph S; Lyamuya E; Wahren B; Sandström E; Biberfeld G; Hoelscher M; Bakari M; Kroidl A; Geldmacher C
J Virol; 2017 Sep; 91(18):. PubMed ID: 28701395
[TBL] [Abstract][Full Text] [Related]
19. Clinically feasible approaches to potentiating cancer cell-based immunotherapies.
Seledtsov VI; Goncharov AG; Seledtsova GV
Hum Vaccin Immunother; 2015; 11(4):851-69. PubMed ID: 25933181
[TBL] [Abstract][Full Text] [Related]
20. HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine.
Shen X; Basu R; Sawant S; Beaumont D; Kwa SF; LaBranche C; Seaton KE; Yates NL; Montefiori DC; Ferrari G; Wyatt LS; Moss B; Alam SM; Haynes BF; Tomaras GD; Robinson HL
J Virol; 2017 Dec; 91(24):. PubMed ID: 29021394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
